This is not the most recent version of the article. View current version (23 NOV 2015)

Intervention Protocol

You have free access to this content

Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function

  1. Juan Pablo Botero Aguirre1,*,
  2. Alejandra Maria Restrepo Hamid2

Editorial Group: Cochrane Kidney and Transplant Group

Published Online: 30 APR 2013

DOI: 10.1002/14651858.CD010481


How to Cite

Botero Aguirre JP, Restrepo Hamid AM. Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD010481. DOI: 10.1002/14651858.CD010481.

Author Information

  1. 1

    Hospital Pablo Tobon Uribe, Medellin, Antioquia, Colombia

  2. 2

    Hospital Pablo Tobon Uribe, Emergency Department, Medellin, Angioquia, Colombia

*Juan Pablo Botero Aguirre, Hospital Pablo Tobon Uribe, Calle 78B #69-240, Medellin, Antioquia, 05001000, Colombia. jpablo146epi@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 30 APR 2013

SEARCH

This is not the most recent version of the article. View current version (23 NOV 2015)

References

Additional references

Adler-Moore 2002
Arendrup 2008
  • Arendrup MC, Fuursted K, Gahrn-Hansen B, Schonheyder HC, Knudsen JD, Jensen IM, et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clinical Microbiology & Infection 2008;14(5):487–94. [MEDLINE: 18294241]
Bassetti 2011
  • Bassetti M, Aversa F, Ballerini F, Benedetti F, Busca A, Cascavilla N, et al. Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients. Clinical Drug Investigation 2011;31(11):745-58. [MEDLINE: 21888451]
Bates 2001
Brown 2012
Del Poeta 2012
  • Del Poeta M, Chaturvedi V. Cryptococcus and cryptococcosis in the twenty-first century. Mycopathologia 2012;173(5-6):283–85. [MEDLINE: 22531978]
Graybill 1996
Hajjeh 2004
  • Hajjeh RA,  Sofair AN,  Harrison LH,  Lyon GM,  Arthington-Skaggs BA,  Mirza SA,  et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. Journal of Clinical Microbiology 2004;42(4):1519-27. [MEDLINE: 15070998]
Higgins 2003
Higgins 2011
  • Higgins JP, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Horwitz 2012
  • Horwitz E,  Shavit O,  Shouval R,  Hoffman A,  Shapiro M,  Moses AE. Evaluating real-life clinical and economical burden of amphotericin-B deoxycholate adverse reactions. International Journal of Clinical Pharmacy 2012;34(4):611-7. [MEDLINE: 22674178]
Husain 2001
  • Husain S,  Wagener MM,  Singh N. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerging infectious diseases 2001;7(3):375-81. [MEDLINE: 11384512]
Johansen 2000
  • Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD000969]
Kleinberg 2006
  • Kleinberg M. What is the current and future status of conventional amphotericin B?. International Journal of Antimicrobial Agents 2006;27 Suppl 1:12–6. [MEDLINE: 16707251]
Laniado-Laborín 2009
McNeil 2001
  • McNeil MM,  Nash SL,  Hajjeh RA,  Phelan MA,  Conn LA,  Plikaytis BD,  et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clinical Infectious Diseases 2001;33(5):641-7. [MEDLINE: 11486286]
Mistro 2012
  • Mistro S, Maciel Ide M, de Menezes RG, Maia ZP, Schooley RT, Badaro R. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clinical Infectious Diseases 2012;54(12):1774-7. [MEDLINE: 22491505]
Noguchi 2012
  • Noguchi S,  Takahashi N,  Ito M,  Teshima K,  Yamashita T,  Michishita Y,  et al. Safety and efficacy of low-dose liposomal amphotericin B as empirical antifungal therapy for patients with prolonged neutropenia. International Journal of Clinical Oncology 2012 Oct [Epub ahead of print]. [DOI: 10.1007/s10147-012-0485-6]
Ostrosky-Zeichner 2003
Pfaller 2005
  • Pfaller MA,  Diekema DJ,  Rinaldi MG,  Barnes R,  Hu B,  Veselov AV,  et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. Journal of Clinical Microbiology 2005;43(12):5848–59. [MEDLINE: 16333066]
Pfaller 2010
Poikonen 2009
  • Poikonen E,  Lyytikäinen O,  Anttila VJ,  Kuusela P,  Koukila-Kähkölä P,  Ollgren J,  et al. Nosocomial candidaemia in a Finnish tertiary care centre during 1987-2004. Scandinavian Journal of Infectious Diseases 2009;41(8):590-6. [MEDLINE: 19488931]
Redbook 2006
  • Cohen HE (editor). Drug topics red book. Montvale: Medical Economics, Inc, 2006.